DOW enters the final week of June carrying one of the worst monthly drawdowns in the commodity chemicals space, with the stock down 16% over the past month to $30.33 — and the Street is catching up with fresh target cuts even as it holds its ratings.
The analyst picture is one of gradual erosion rather than outright capitulation. Citigroup cut its target on DOW twice in four weeks: first from $48 to $41 in late May, and then again today to $35, while maintaining its Buy rating. That is a $13 target reduction in under a month from a firm that still nominally likes the stock. UBS similarly trimmed to $37 while staying at Neutral. Both moves point to the same conclusion — the Street has not abandoned Dow, but it keeps marking down what the stock is worth. The consensus mean target now sits at $41.88, implying roughly 38% upside from current levels, though that figure is being pulled higher by older, stale targets from RBC at $51 and BMO at $46 that were set in late April. Strip those out, and the forward picture looks considerably more modest.
The bull case rests on margin expansion from new production capacity, anti-dumping protections reducing import pressure into polyethylene chains, and seasonality lifting the Performance Materials segment. The bear case is harder to dismiss right now: demand weakness across industrial and consumer end markets is real, energy costs remain elevated, and tariff uncertainty is a persistent drag. On fundamentals, valuation multiples have compressed sharply — the price-to-book ratio has fallen 0.20 over the past month to 1.32, and the P/E has dropped 1.6 turns to 12.2x. Those are not expensive levels, but they reflect a market pricing in a prolonged trough, not an imminent recovery. EPS surprise ranks in the 93rd percentile historically, and the 90-day EPS momentum factor score is a perfect 100 — meaning estimates have been revised higher over that window — yet the 30-day reading has collapsed to just 27. That divergence suggests the estimate upgrade cycle that followed Q1 results has stalled out.
The lending market tells a quieter story than the price action might imply. Short interest is modest at 3.65% of the free float, and while it has risen roughly 5% over the past month, there has been no aggressive build this week — shares short actually ticked down 1.4% on the day. More telling is the availability picture: borrow is extraordinarily loose, with availability running at 3,218% of short interest, meaning the lending pool dwarfs what shorts have actually deployed. That has fallen sharply from above 5,000% earlier this month as the stock has sold off, but the absolute level remains far into "no constraint" territory. Cost to borrow is negligible at 0.36%, down 10% on the week. The ORTEX short score is 34.3 — below the midpoint and broadly flat over the past two weeks — confirming that short-side pressure is not the engine driving the decline. Options positioning is modestly defensive: the put/call ratio is 1.13, near the top of its 52-week range of 0.66–1.19, though just 0.6 standard deviations above its 20-day average. Cautious, but not alarmed.
The sector context reinforces that this is not an idiosyncratic Dow story. LYB, the closest peer by correlation, fell 9% on the week. CE dropped 10.5%. WLK lost 12.5%, and OLN declined 15%. Commodity chemicals are broadly under pressure, and DOW's 8% weekly slide sits in the middle of that peer range — underperforming LYB but holding up better than OLN and WLK. That relative positioning matters: DOW is not being singled out, but its steeper year-to-date slide of roughly 18% suggests the market views its margin recovery timeline as longer than peers'.
Q2 earnings arrive on July 23. The last print — Q1 on April 23 — moved the stock just -0.4% on the day before recovering to a 4.3% gain over the following week, suggesting actual results have been less bad than feared. With targets being cut heading into the release and the stock now trading below some analysts' bear-case scenarios, the July 23 print becomes the next clear test of whether the derating has run its course.
See the live data behind this article on ORTEX.
Open DOW on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
